CD123 and its potential clinical application in leukemias

Area of Science:

• Immunology
• Oncology
• Molecular Biology

Background:

• The interleukin 3 receptor (IL-3R) is formed by the IL-3R alpha (CD123) chain and the beta c (βc) subunit.
• CD123 is highly expressed on various cells, including leukemia stem cells (LSCs).
• Aberrant CD123 expression is associated with the initiation and progression of hematologic malignancies like AML and ALL.

Purpose of the Study:

• To review the biological functions of CD123.
• To discuss the potential clinical applications of CD123 as a biomarker.
• To explore the clinical prospects of CD123 in disease diagnosis, targeted therapy, and prognosis.

Main Methods:

• Literature review of existing research on CD123.
• Analysis of studies investigating CD123 expression in various diseases.
• Evaluation of CD123's role in disease pathogenesis and its potential as a therapeutic target.

Main Results:

• CD123 is a significant marker for identifying and potentially targeting LSCs.
• High CD123 expression correlates with disease progression in AML and ALL.
• CD123 shows promise as a biomarker for diagnosis and prognosis.

Conclusions:

• CD123 is a crucial factor in the pathogenesis of certain hematologic malignancies.
• Targeting CD123 presents a promising therapeutic strategy.
• Further research into CD123's clinical utility is warranted for improved patient outcomes.